The Role of Bridging Therapy in Hepatocellular Carcinoma

Table 2

Comparison of patients, characteristics.

Comparison of patients’ characteristics; Bridging therapy versus nonbridging therapy
	BT	Non-BT	Sig
Age	59.4	55.9	0.47
Sex (male)	16	58	0.46
AFP	168	160	0.98
MELD	13	16	0.86
Waiting time	59.5	152.1	0.09
Vascular invasion	5	15	0.45
Multiple	7	33	0.32
Size > 3 cm	7	11	0.04*
HCV	11	36	0.26

∗Statistically significant (𝑃<0.05).
Bridging therapy (BT);  alpha-fetoprotein (AFP);  hepatitis C cirrhosis (HCV).